CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects

Autor: Zhu, L., Bruggemann, R.J.M., Uy, J., Colbers, A., Hruska, M.W., Chung, E., Sims, K., Vakkalagadda, B., Xu, X., Schaik, R.H. van, Burger, D.M., Bertz, R.J.

Publikováno v: Journal of Clinical Pharmacology, 57(2), 235-246. Wiley-Blackwell
Journal of Clinical Pharmacology and Journal of New Drugs, 57, 2, pp. 235-246
Journal of Clinical Pharmacology and Journal of New Drugs, 57, 235-246

Contains fulltext : 169911.pdf (Publisher’s version ) (Closed access) Voriconazole, a broad-spectrum triazole antifungal agent, is metabolized by cytochrome P450 (CYP) 2C19 and, to a lesser extent, by CYP3A. Genetic polymorphism of CYP2C19 not only

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::48142bcc2eaa0d23ac6f5a351153e4bf
https://doi.org/10.1002/jcph.798